Skip to main content
72°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by NGM Biopharmaceuticals, Inc.
NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum
July 17, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Announces Closing of Tender Offer
April 05, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
March 19, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
March 11, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
February 26, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
February 20, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
January 17, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
January 09, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
November 13, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio to Participate in Upcoming Investor Conferences
November 07, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
November 02, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®
October 11, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights
August 03, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio to Participate in Upcoming Investor Conferences
May 25, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023
May 08, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data
May 04, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
January 12, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
January 09, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting
December 12, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting
December 07, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting
November 07, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting
November 04, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results
November 03, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
October 17, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting
November 03, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
October 16, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NGM
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.